Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gosewisch

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 29, 2019
First-in-human <sup>18</sup>F-SiFAlin-TATE PET/CT for NET imaging and theranosticsHarun Ilhan, A Todica, S Lindner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 22, 2020
Image-based dosimetry for <sup>225</sup>Ac-PSMA-I&T therapy using quantitative SPECTA Gosewisch, M Schleske, F J Gildehaus, et al.
Nuclear Medicine and Biology|March 24, 2018
Evaluation of <sup>177</sup>Lu[Lu]-CHX-A″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XIIL Fiedler, M Kellner, A Gosewisch, et al.
BMC Cancer|August 10, 2019
Salvage PRRT with <sup>177</sup>Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survivalS Rudisile, A Gosewisch, V Wenter, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
European Journal of Nuclear Medicine and Molecular Imaging|July 29, 2019
First-in-human <sup>18</sup>F-SiFAlin-TATE PET/CT for NET imaging and theranosticsHarun Ilhan, A Todica, S Lindner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 22, 2020
Image-based dosimetry for <sup>225</sup>Ac-PSMA-I&T therapy using quantitative SPECTA Gosewisch, M Schleske, F J Gildehaus, et al.
Nuclear Medicine and Biology|March 24, 2018
Evaluation of <sup>177</sup>Lu[Lu]-CHX-A″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XIIL Fiedler, M Kellner, A Gosewisch, et al.
BMC Cancer|August 10, 2019
Salvage PRRT with <sup>177</sup>Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survivalS Rudisile, A Gosewisch, V Wenter, et al.
Pageof 1